XBIOTECH INC. overview

...

...

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. -- XBIT PR Newswire NEW YORK, May 16, 2017 NEW YORK , May 16, 2017 /PRNewswire/ -- Levi & Korsinsky, LLP announces it has commenced an investigation of XBiotech Inc. ("XBiotech") (NASDAQ: XBIT) concerning possible violations of federal securities laws. On April 20, 2017 , XBiotech announced that the European Medicines Agency rendered a...

NEW YORK, NY / ACCESSWIRE / May 4, 2017 / XBiotech, Inc. (NASDAQ: XBIT ) will be discussing their earnings results in their Q1 Earnings Call to be held Thursday, May 04, 2017 at 8:30 AM Eastern Time. To listen to the event live – visit https://www.investornetwork.com/company/23193 . Replay Information The replay will be available online at https://www.investornetwork.com/company/23193 . About Investor Network Investor Network (IN) is a new financial content community, serving millions of...

XBIOTECH NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In XBiotech, Inc. To Contact The Firm PR Newswire NEW YORK, April 21, 2017 NEW YORK , April 21, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at XBiotech, Inc. ("XBiotech" or the "Company") (NASDAQ: XBIT). The investigation focuses on whether the Company and its executives violated federal securities laws. Specifically,...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT PR Newswire NEW YORK, April 21, 2017 NEW YORK , April 21, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or the "Company") (NASDAQ: XBIT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The investigation concerns whether Xbiotech and certain of its officers and/or...

AUSTIN, Texas, Jan. 17, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced the publication of results from its pivotal phase 3 trial of the Company’s lead monoclonal antibody therapy. The results were published in The Lancet Oncology in an article titled, “ MABp1 as a Novel Antibody Treatment for Advanced Colorectal Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study.” The article is now available online. “The findings indicate what we believe to be...